Indian Journal of Dermatology, Venereology and Leprology
Medknow Publications on behalf of The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
Vol. 73, No. 2, 2007, pp. 133-137
Bioline Code: dv07047
Full paper language: English
Document type: Research Article
Document available free of charge
Indian Journal of Dermatology, Venereology and Leprology, Vol. 73, No. 2, 2007, pp. 133-137
© Copyright 2007 Indian Journal of Dermatology, Venereology and Leprology.
Focus - Use of fumaric acid esters in psoriasis|
Roll, Antonie; Reich, Kristian & Böer, Almut
Fumaric acid esters (FAE) are chemical compounds derived from the unsaturated dicarbonic acid fumaric acid. The usage of FAEs in treatment of psoriasis was introduced in the late 1950′s. In the 1980s more standardized oral preparations of FAEs were developed containing dimethylfumarate(DMF) and salts of monoethylfumarate(MEF) as main compounds. In 1994, Fumaderm ® an enteric-coated tablet containing DMF and calcium, magnesium, and zinc salts of MEF was approved for the treatment of psoriasis in Germany and since then has become the most commonly used systemic therapy in this country. Fumaric acids have been proven to be an effective therapy in patients with psoriasis even though the mechanisms of action are not completely understood. About 50-70% of the patients achieve PASI 75 improvement within four months of treatment and without any long-term toxicity, immunosuppressive effects, or increased risk of infection or malignancy. Tolerance is limited by gastrointestinal side effects and flushing of the skin. This article reviews pharmacokinetics, uses, contraindications, dosages, and side effects of treatment with FAEs.
Fumaric acid ester, Psoriasis
Alternative site location: http://www.ijdvl.com